https://transhumanist.ru/index.php?action=history&feed=atom&title=STK11 2026-10-05T06:34:44Z История изменений этой страницы в вики MediaWiki 1.43.6 https://transhumanist.ru/index.php?title=STK11&diff=3949&oldid=prev 2021-04-29T18:53:12Z

<p>Новая страница: «Serine/threonine-protein kinase STK11 precursor (EC 2.7.11.1) (Liver kinase B1) (LKB1) (hLKB1) (Renal carcinoma antigen NY-REN-19) [LKB1] [PJS] ==Publications==...»</p> <p><b>Новая страница</b></p><div>Serine/threonine-protein kinase STK11 precursor (EC 2.7.11.1) (Liver kinase B1) (LKB1) (hLKB1) (Renal carcinoma antigen NY-REN-19) [LKB1] [PJS]<br /> <br /> ==Publications==<br /> <br /> {{medline-entry<br /> |title=A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.<br /> |pubmed-url=https://pubmed.ncbi.nlm.nih.gov/28407996<br /> |abstract=The National Comprehensive Cancer Network recommends that women who carry gene variants that confer substantial risk for breast cancer consider risk-reduction strategies, that is, enhanced surveillance (breast magnetic resonance imaging and mammography) or prophylactic surgery. Pathogenic variants can be detected in women with a family history of breast or ovarian cancer syndromes by multigene panel testing. To investigate whether using a seven-gene test to identify women who should consider risk-reduction strategies could cost-effectively increase life expectancy. We estimated effectiveness and lifetime costs from a payer perspective for two strategies in two hypothetical cohorts of women (40-year-old and 50-year-old cohorts) who meet the National Comprehensive Cancer Network-defined family history criteria for multigene testing. The two strategies were the usual test strategy for variants in [[BRCA1]] and [[BRCA2]] and the seven-gene test strategy for variants in [[BRCA1]], [[BRCA2]], [[TP53]], [[PTEN]], [[CDH1]], [[STK11]], and [[PALB2]]. Women found to have a pathogenic variant were assumed to undergo either prophylactic surgery or enhanced surveillance. The incremental cost-effectiveness ratio for the seven-gene test strategy compared with the [[BRCA1]]/2 test strategy was $42,067 per life-year gained or $69,920 per quality-adjusted life-year gained for the 50-year-old cohort and $23,734 per life-year gained or $48,328 per quality-adjusted life-year gained for the 40-year-old cohort. In probabilistic sensitivity analysis, the seven-gene test strategy cost less than $100,000 per life-year gained in 95.7% of the trials for the 50-year-old cohort. Testing seven breast cancer-associated genes, followed by risk-reduction management, could cost-effectively improve life expectancy for women at risk of hereditary breast cancer.<br /> |mesh-terms=* Adult<br /> * Age Factors<br /> * Aged<br /> * Aged, 80 and over<br /> * Biomarkers, Tumor<br /> * Breast Neoplasms<br /> * Cost-Benefit Analysis<br /> * Decision Support Techniques<br /> * Early Detection of Cancer<br /> * Female<br /> * Gene Expression Profiling<br /> * Genetic Predisposition to Disease<br /> * Genetic Testing<br /> * Health Care Costs<br /> * Heredity<br /> * Humans<br /> * Life Expectancy<br /> * Magnetic Resonance Imaging<br /> * Mammography<br /> * Mastectomy<br /> * Middle Aged<br /> * Models, Economic<br /> * Patient Selection<br /> * Phenotype<br /> * Predictive Value of Tests<br /> * Prognosis<br /> * Quality-Adjusted Life Years<br /> * Risk Assessment<br /> * Risk Factors<br /> * Watchful Waiting<br /> |keywords=* BRCA<br /> * breast cancer<br /> * cost-effectiveness<br /> * multigene panel testing<br /> |full-text-url=https://sci-hub.do/10.1016/j.jval.2017.01.006<br /> }}</div>

OdysseusBot